Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model

Clinical and Vaccine Immunology

Volumn 15, Issue 5, 2008, Pages 750-756

  Irwin, S M ^a   Goodyear, A ^a   Keyser, A ^a   Christensen, R ^a   Troudt, J M ^a   Taylor, J L ^a   Bohsali, A ^b   Briken, V ^b   Izzo, A A ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Bldg 142   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INTERLEUKIN 12; BACTERIUM ANTIBODY;

ADAPTIVE IMMUNITY; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BONE MARROW; CD8+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENOMICS; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SWEDEN; TUBERCULOSIS; VACCINATION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GENE DELETION; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; BCG VACCINE; DISEASE MODELS, ANIMAL; GENE DELETION; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; VACCINATION;

EID: 46249105598     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00018-08     Document Type: Article

References (31)

1. Bedwell, J., S. K. Kairo, M. A. Behr, and J. A. Bygraves. 2001. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 19:2146-2151.
2. Behr, M. A. 2002. BCG - different strains, different vaccines? Lancet Infect. Dis. 2:86-92.
3. Behr, M. A. 2001. Comparative genomics of BCG vaccines. Tuberculosis (Edinburgh) 81:165-168.
4. Behr, M. A. 2001. Correlation between BCG genomics and protective efficacy. Scand. J. Infect. Dis. 33:249-252.
5. Behr, M. A., and P. M. Small. 1997. Has BCG attenuated to impotence? Nature 389:133-134.
6. Behr, M. A., and P. M. Small. 1999. A historical and molecular phylogeny of BCG strains. Vaccine 17:915-922.
7. Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520-1523.
8. Brewer, T. F., and G. A. Colditz. 1995. Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis. 20:126-135.
9. Castillo-Rodal, A. I., M. Castanon-Arreola, R. Hernandez-Pando, J. J. Calva, E. Sada-Diaz, and Y. Lopez-Vidal. 2006. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect. Immun. 74:1718-1724.
10. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247.
11. Dao, D. N., L. Kremer, Y. Guerardel, A. Molano, W. R. Jacobs, Jr., S. A. Porcelli, and V. Briken. 2004. Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect. Immun. 72:2067-2074.
12. Fine, P. E., and E. Vynnycky. 1998. The effect of heterologous immunity upon the apparent efficacy of (e.g., BCG) vaccines. Vaccine 16:1923-1928.
13. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254.
14. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:1602-1609.
15. Gruppo, V., and I. M. Orme. 2002. Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 82:267-273.
16. Huygen, K., D. Abramowicz, P. Vandenbussche, F. Jacobs, J. De Bruyn, A. Kentos, A. Drowart, J. P. Van Vooren, and M. Goldman. 1992. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect. Immun. 60:2880-2886.
17. Irwin, S. M., A. A. Izzo, S. W. Dow, Y. A. Skeiky, S. G. Reed, M. R. Alderson, and I. M. Orme. 2005. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect. Immun. 73: 5809-5816.
18. Izzo, A., L. Brandt, T. Lasco, A. P. Kipnis, and I. Orme. 2005. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinburgh) 85:25-28.
19. Kaplan, G. 2005. Rational vaccine development - a new trend in tuberculosis control. N. Engl. J. Med. 353:1624-1625.
20. Lagranderie, M. R., A. M. Balazuc, E. Deriaud, C. D. Leclerc, and M. Gheorghiu. 1996. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 64:1-9.
21. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
22. Mostowy, S., A. G. Tsolaki, P. M. Small, and M. A. Behr. 2003. The in vitro evolution of BCG vaccines. Vaccine 21:4270-4274.
23. North, R. J., and Y. J. Jung. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22:599-623.
24. Oettinger, T., M. Jorgensen, A. Ladefoged, K. Haslov, and P. Andersen. 1999. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber. Lung Dis. 79:243-250.
25. Olsen, A. W., L. Brandt, E. M. Agger, L. A. van Pinxteren, and P. Andersen. 2004. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand. J. Immunol. 60:273-277.
26. Orme, I. M. 2005. The use of animal models to guide rational vaccine design. Microbes Infect. 7:905-910.
27. Power, C. A., G. Wei, and P. A. Bretscher. 1998. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intra-dermal route. Infect. Immun. 66:5743-5750.
28. Roach, D. R., H. Briscoe, B. Saunders, M. P. France, S. Riminton, and W. J. Britton. 2001. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J. Exp. Med. 193:239-246.
29. Romano, M., V. Roupie, X. M. Wang, O. Denis, F. Jurion, P. Y. Adnet, R. Laali, and K. Huygen. 2006. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 118:321-332.
30. Skeiky, Y. A., and J. C. Sadoff. 2006. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4:469-476.
31. Smith, D., G. Harding, J. Chan, M. Edwards, J. Hank, D. Muller, and F. Sobhi. 1979. Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs. J. Biol. Stand. 7:179-197.